Pelvic Discontinuity Treated with Custom Triflange Component: a Reliable Option
Overview
Authors
Affiliations
Background: Pelvic discontinuity is an increasingly common complication of THA. Treatments of this complex situation are varied, including cup-cage constructs, acetabular allografts with plating, pelvic distraction technique, and custom triflange acetabular components. It is unclear whether any of these offer substantial advantages.
Questions/purposes: We therefore determined (1) revision and overall survival rates, (2) discontinuity healing rate, and (3) Harris hip score (HHS) after treatment of pelvic discontinuity with a custom triflange acetabular component and (4) the cost of this reconstructive operation compared to other constructs.
Methods: We retrospectively reviewed 57 patients with pelvic discontinuity treated with revision THA using a custom triflange acetabular component. We reviewed operative reports, radiographs, and clinical data for clinical and radiographic results. We also performed a cost comparison with utilization of other techniques. Minimum followup was 24 months (average, 65 months; range, 24-215 months).
Results: Fifty-six of 57 (98%) were free of revision for aseptic loosening at latest followup. Fifty-four (95%) were free of revision of the triflange component for any reason. Thirty-seven (65%) were free of revision for any reason. Twenty-eight (49%) were free of revision for any reason and free of any component migration and had a healed discontinuity. Forty-six (81%) had a stable triflange component with a healed pelvic discontinuity. Average HHS was 74.8. The costs of the custom triflange implants and a Trabecular Metal cup-cage construct were equivalent: $12,500 and $11,250, respectively.
Conclusions: In this group of patients with osteolytic pelvic discontinuity, triflange implants provided predictable mid-term fixation at a cost equivalent to other treatment methods.
Level Of Evidence: Level IV, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence.
Wake N, Lin Y, Tan E, Sneag D, Ianucci S, Fung M 3D Print Med. 2024; 10(1):36.
PMID: 39540982 PMC: 11562346. DOI: 10.1186/s41205-024-00239-6.
Management of acetabular bone loss in revision total hip replacement: a narrative literature review.
Pandey A, Zuke W, Surace P, Kamath A Ann Jt. 2024; 9:21.
PMID: 38694811 PMC: 11061657. DOI: 10.21037/aoj-23-23.
Alter T, Hadley M, Couch C, Fruth K, Bedard N, Perry K J Arthroplasty. 2024; 39(9S1):S194-S202.
PMID: 38599525 PMC: 11473099. DOI: 10.1016/j.arth.2024.03.071.
Broekhuis D, Tordoir R, Vallinga Z, Schoones J, Pijls B, Nelissen R EFORT Open Rev. 2023; 8(7):522-531.
PMID: 37395708 PMC: 10321047. DOI: 10.1530/EOR-22-0081.
Humphrey T, Baker C, Courtney P, Paprosky W, Bedair H, Sheth N Hip Pelvis. 2023; 35(2):122-132.
PMID: 37323551 PMC: 10264228. DOI: 10.5371/hp.2023.35.2.122.